N-type calcium channel (Cav2.2) (Cav2.2)

N-type calcium channels (Cav2.2) are high-voltage-activated, voltage-gated ion channels primarily expressed in neurons, especially at presynaptic terminals and dendrites[1][9]. They are essential mediators of neurotransmitter release in both the central and peripheral nervous systems, playing a critical role in synaptic transmission, pain processing (nociception), and neuroendocrine functions[1][4][9]. The main pore-forming subunit α1B is encoded by the CACNA1B gene and is modulated by auxiliary α2δ and β subunits[1]. Pharmaceutical blockade of N-type channels—using selective agents such as ziconotide (Prialt) or ω-conotoxins—interrupts pain signaling and is clinically validated for treating severe chronic and intractable pain, especially in patients unresponsive to opioids[5][6]. The highly neuron-specific expression of Cav2.2, its central role in neurotransmitter release, and validated druggability make it a major molecular target for analgesic drug discovery. However, therapeutic use of N-type channel inhibitors, particularly ziconotide, is limited by a narrow safety margin and neuropsychiatric side effects[2][5].

Other names

N-type Ca²⁺ channelN-type calcium channelVoltage-dependent N-type calcium channelCav2.2 channelCalcium channel, voltage-dependent, N typeAlpha-1B subunit (CACNA1B)

Blockade of voltage-gated N-type Ca²⁺ channels, interrupting presynaptic calcium influx; Inhibition of neurotransmitter (e.g., glutamate, substance P, CGRP) release; Modulation of nociceptive (pain) signaling pathways